{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T01:12:55Z","timestamp":1792026775403,"version":"4.4.0"},"reference-count":46,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2023,4,1]]},"abstract":"<jats:sec><jats:title>Importance<\/jats:title><jats:p>Pre\u2013heart failure with preserved ejection fraction (pre-HFpEF) is common and has no specific therapy aside from cardiovascular risk factor management.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To investigate the hypothesis that sacubitril\/valsartan vs valsartan would reduce left atrial volume index using volumetric cardiac magnetic resonance imaging in patients with pre-HFpEF.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>The Personalized Prospective Comparison of ARNI [angiotensin receptor\/neprilysin inhibitor] With ARB [angiotensin-receptor blocker] in Patients With Natriuretic Peptide Elevation (PARABLE) trial was a prospective, double-blind, double-dummy, randomized clinical trial carried out over 18 months between April 2015 and June 2021. The study was conducted at a single outpatient cardiology center in Dublin, Ireland. Of 1460 patients in the STOP-HF program or outpatient cardiology clinics, 461 met initial criteria and were approached for inclusion. Of these, 323 were screened and 250 asymptomatic patients 40 years and older with hypertension or diabetes, elevated B-type natriuretic peptide (BNP) greater than 20 pg\/mL or N-terminal pro-b-type natriuretic peptide greater than 100 pg\/mL, left atrial volume index greater than 28 mL\/m<jats:sup>2<\/jats:sup>, and preserved ejection fraction greater than 50% were included.<\/jats:p><\/jats:sec><jats:sec><jats:title>Interventions<\/jats:title><jats:p>Patients were randomized to angiotensin receptor neprilysin inhibitor sacubitril\/valsartan titrated to 200 mg twice daily or matching angiotensin receptor blocker valsartan titrated to 160 mg twice daily.<\/jats:p><\/jats:sec><jats:sec><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>Maximal left atrial volume index and left ventricular end diastolic volume index, ambulatory pulse pressure, N-terminal pro-BNP, and adverse cardiovascular events.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among the 250 participants in this study, the median (IQR) age was 72.0 (68.0-77.0) years; 154 participants (61.6%) were men and 96 (38.4%) were women. Most (n\u2009=\u2009245 [98.0%]) had hypertension and 60 (24.0%) had type 2 diabetes. Maximal left atrial volume index was increased in patients assigned to receive sacubitril\/valsartan (6.9 mL\/m<jats:sup>2<\/jats:sup>; 95% CI, 0.0 to 13.7) vs valsartan (0.7 mL\/m<jats:sup>2<\/jats:sup>; 95% CI, \u22126.3 to 7.7; <jats:italic>P<\/jats:italic>\u2009&amp;amp;lt;\u2009.001) despite reduced markers of filling pressure in both groups. Changes in pulse pressure and N-terminal pro-BNP were lower in the sacubitril\/valsartan group (\u22124.2 mm Hg; 95% CI, \u22127.2 to \u22121.21 and \u221217.7%; 95% CI, \u221236.9 to 7.4, respectively; <jats:italic>P<\/jats:italic>\u2009&amp;amp;lt;\u2009.001) than the valsartan group (\u22121.2 mm Hg; 95% CI, \u22124.1 to 1.7 and 9.4%; 95% CI, \u221215.6 to 4.9, respectively; <jats:italic>P<\/jats:italic>\u2009&amp;amp;lt;\u2009.001). Major adverse cardiovascular events occurred in 6 patients (4.9%) assigned to sacubitril\/valsartan and 17 (13.3%) assigned to receive valsartan (adjusted hazard ratio, 0.38; 95% CI, 0.17 to 0.89; adjusted <jats:italic>P<\/jats:italic>\u2009=\u2009.04).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions and Relevance<\/jats:title><jats:p>In this trial of patients with pre-HFpEF, sacubitril\/valsartan treatment was associated with a greater increase in left atrial volume index and improved markers of cardiovascular risk compared to valsartan. More work is needed to understand the observed increased cardiac volumes and long-term effects of sacubitril\/valsartan in patients with pre-HFpEF.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial Registration<\/jats:title><jats:p>ClinicalTrials.gov Identifier: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04687111\">NCT04687111<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamacardio.2023.0065","type":"journal-article","created":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T16:05:05Z","timestamp":1678291505000},"page":"366","source":"Crossref","is-referenced-by-count":54,"title":["Effect of Sacubitril\/Valsartan vs Valsartan on Left Atrial Volume in Patients With Pre\u2013Heart Failure With Preserved Ejection Fraction"],"prefix":"10.1001","volume":"8","author":[{"given":"Mark","family":"Ledwidge","sequence":"first","affiliation":[{"name":"St Vincent\u2019s Screening to Prevent Heart Failure (STOP-HF) Unit, St Vincent\u2019s University Healthcare Group, Dublin, Ireland"},{"name":"School of Medicine, University College Dublin, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan D.","family":"Dodd","sequence":"additional","affiliation":[{"name":"School of Medicine, University College Dublin, Dublin, Ireland"},{"name":"Department of Radiology, St Vincent\u2019s University Hospital, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Ryan","sequence":"additional","affiliation":[{"name":"St Vincent\u2019s Screening to Prevent Heart Failure (STOP-HF) Unit, St Vincent\u2019s University Healthcare Group, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Sweeney","sequence":"additional","affiliation":[{"name":"St Vincent\u2019s Screening to Prevent Heart Failure (STOP-HF) Unit, St Vincent\u2019s University Healthcare Group, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"McDonald","sequence":"additional","affiliation":[{"name":"St Vincent\u2019s Screening to Prevent Heart Failure (STOP-HF) Unit, St Vincent\u2019s University Healthcare Group, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Fox","sequence":"additional","affiliation":[{"name":"St Vincent\u2019s Screening to Prevent Heart Failure (STOP-HF) Unit, St Vincent\u2019s University Healthcare Group, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Shorten","sequence":"additional","affiliation":[{"name":"St Vincent\u2019s Screening to Prevent Heart Failure (STOP-HF) Unit, St Vincent\u2019s University Healthcare Group, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuaiwei","family":"Zhou","sequence":"additional","affiliation":[{"name":"St Vincent\u2019s Screening to Prevent Heart Failure (STOP-HF) Unit, St Vincent\u2019s University Healthcare Group, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Watson","sequence":"additional","affiliation":[{"name":"St Vincent\u2019s Screening to Prevent Heart Failure (STOP-HF) Unit, St Vincent\u2019s University Healthcare Group, Dublin, Ireland"},{"name":"School of Medicine, University College Dublin, Dublin, Ireland"},{"name":"School of Medicine, Dentistry and Biomedical Sciences, Wellcome-Wolfson Institute for Experimental Medicine, Queens University, Belfast, Northern Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Gallagher","sequence":"additional","affiliation":[{"name":"School of Medicine, University College Dublin, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niall","family":"McVeigh","sequence":"additional","affiliation":[{"name":"School of Medicine, University College Dublin, Dublin, Ireland"},{"name":"Department of Radiology, St Vincent\u2019s University Hospital, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Murphy","sequence":"additional","affiliation":[{"name":"School of Medicine, University College Dublin, Dublin, Ireland"},{"name":"Department of Radiology, St Vincent\u2019s University Hospital, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"McDonald","sequence":"additional","affiliation":[{"name":"St Vincent\u2019s Screening to Prevent Heart Failure (STOP-HF) Unit, St Vincent\u2019s University Healthcare Group, Dublin, Ireland"},{"name":"School of Medicine, University College Dublin, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"18","key":"hoi230003r1","doi-asserted-by":"publisher","first-page":"e895","DOI":"10.1161\/CIR.0000000000001063","article-title":"2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines.","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"issue":"1","key":"hoi230003r2","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1001\/jama.2013.7588","article-title":"Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial.","volume":"310","author":"Ledwidge","year":"2013","journal-title":"JAMA"},{"issue":"18","key":"hoi230003r3","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1056\/NEJMoa0801369","article-title":"Treatment of hypertension in patients 80 years of age or older.","volume":"358","author":"Beckett","year":"2008","journal-title":"N Engl J Med"},{"issue":"22","key":"hoi230003r4","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","article-title":"A randomized trial of intensive versus standard blood-pressure control.","volume":"373","author":"Wright","year":"2015","journal-title":"N Engl J Med"},{"issue":"11","key":"hoi230003r5","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1016\/j.jacc.2006.03.034","article-title":"Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study.","volume":"47","author":"Scirica","year":"2006","journal-title":"J Am Coll Cardiol"},{"issue":"22","key":"hoi230003r6","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes.","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"issue":"7","key":"hoi230003r7","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes.","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"hoi230003r8","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes.","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"issue":"15","key":"hoi230003r9","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease.","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"issue":"5","key":"hoi230003r10","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.","volume":"325","author":"Yusuf","year":"1991","journal-title":"N Engl J Med"},{"issue":"12","key":"hoi230003r11","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1161\/CIRCULATIONAHA.106.666818","article-title":"Prevalence and prognostic significance of heart failure stages: application of the American College of Cardiology\/American Heart Association heart failure staging criteria in the community.","volume":"115","author":"Ammar","year":"2007","journal-title":"Circulation"},{"issue":"1","key":"hoi230003r12","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2018-000840","article-title":"Prevalence of early stages of heart failure in an elderly risk population: the Copenhagen Heart Failure Risk Study.","volume":"6","author":"Gaborit","year":"2019","journal-title":"Open Heart"},{"issue":"1","key":"hoi230003r13","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-039869","article-title":"Observational study investigating the prevalence of asymptomatic stage B heart failure in patients with type 2 diabetes who are not known to have coronary artery disease.","volume":"11","author":"Oo","year":"2021","journal-title":"BMJ Open"},{"issue":"19","key":"hoi230003r14","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1056\/NEJMoa032566","article-title":"Diastolic heart failure\u2013abnormalities in active relaxation and passive stiffness of the left ventricle.","volume":"350","author":"Zile","year":"2004","journal-title":"N Engl J Med"},{"issue":"7","key":"hoi230003r15","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1161\/CIRCULATIONAHA.106.638569","article-title":"Diastolic heart failure: evidence of increased myocardial collagen turnover linked to diastolic dysfunction.","volume":"115","author":"Martos","year":"2007","journal-title":"Circulation"},{"issue":"6","key":"hoi230003r16","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1161\/CIRCHEARTFAILURE.112.968594","article-title":"Comorbidity and ventricular and vascular structure and function in heart failure with preserved ejection fraction: a community-based study.","volume":"5","author":"Mohammed","year":"2012","journal-title":"Circ Heart Fail"},{"issue":"10","key":"hoi230003r17","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1161\/CIRCRESAHA.121.318159","article-title":"From systemic inflammation to myocardial fibrosis: the heart failure with preserved ejection fraction paradigm revisited.","volume":"128","author":"Paulus","year":"2021","journal-title":"Circ Res"},{"issue":"25","key":"hoi230003r18","doi-asserted-by":"publisher","first-page":"2882","DOI":"10.1161\/CIRCULATIONAHA.111.048520","article-title":"Sildenafil and B-type natriuretic peptide acutely phosphorylate titin and improve diastolic distensibility in vivo.","volume":"124","author":"Bishu","year":"2011","journal-title":"Circulation"},{"issue":"10","key":"hoi230003r19","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.115.003238","article-title":"Left atrial remodeling and atrioventricular coupling in a canine model of early heart failure with preserved ejection fraction.","volume":"9","author":"Zakeri","year":"2016","journal-title":"Circ Heart Fail"},{"issue":"8","key":"hoi230003r20","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1113\/jphysiol.2011.218271","article-title":"Effect of ageing on left ventricular compliance and distensibility in healthy sedentary humans.","volume":"590","author":"Fujimoto","year":"2012","journal-title":"J Physiol"},{"issue":"9","key":"hoi230003r21","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1056\/NEJMc1615918","article-title":"Heart failure with preserved ejection fraction","volume":"376","author":"Redfield","year":"2017","journal-title":"N Engl J Med"},{"issue":"6","key":"hoi230003r22","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1161\/CIRCULATIONAHA.114.009625","article-title":"Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction.","volume":"131","author":"Mohammed","year":"2015","journal-title":"Circulation"},{"issue":"11","key":"hoi230003r23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0049259","article-title":"Modest elevation in BNP in asymptomatic hypertensive patients reflects sub-clinical cardiac remodeling, inflammation and extracellular matrix changes.","volume":"7","author":"Phelan","year":"2012","journal-title":"PLoS One"},{"issue":"14","key":"hoi230003r24","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1016\/j.jacc.2019.08.020","article-title":"Myocardial aging, the cardiac atria, and BNP: what does it all mean?","volume":"74","author":"Burnett","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"hoi230003r25","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.jacbts.2021.05.001","article-title":"STOP-HF Trial: higher endogenous BNP and cardiovascular protection in subjects at risk for heart failure.","volume":"6","author":"Cannone","year":"2021","journal-title":"JACC Basic Transl Sci"},{"issue":"1","key":"hoi230003r26","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.114.013255","article-title":"Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial.","volume":"131","author":"Pfeffer","year":"2015","journal-title":"Circulation"},{"issue":"16","key":"hoi230003r27","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction.","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"issue":"12","key":"hoi230003r28","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction.","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"issue":"9851","key":"hoi230003r29","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1016\/S0140-6736(12)61227-6","article-title":"The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial.","volume":"380","author":"Solomon","year":"2012","journal-title":"Lancet"},{"issue":"17","key":"hoi230003r30","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction.","volume":"381","author":"Solomon","year":"2019","journal-title":"N Engl J Med"},{"issue":"9","key":"hoi230003r32","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1161\/CIRCULATIONAHA.118.034646","article-title":"A simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction.","volume":"138","author":"Reddy","year":"2018","journal-title":"Circulation"},{"issue":"3","key":"hoi230003r33","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1002\/ejhf.v23.3","article-title":"Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and writing committee of the Universal Definition of Heart Failure: endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association.","volume":"23","author":"Bozkurt","year":"2021","journal-title":"Eur J Heart Fail"},{"issue":"24","key":"hoi230003r34","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1093\/eurheartj\/ehab082","article-title":"The struggle towards a universal definition of heart failure-how to proceed?","volume":"42","author":"Cleland","year":"2021","journal-title":"Eur Heart J"},{"issue":"6","key":"hoi230003r35","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1093\/eurheartj\/ehaa758","article-title":"The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the Heart \u2018omics\u2019 in Ageing (HOMAGE) randomized clinical trial.","volume":"42","author":"Cleland","year":"2021","journal-title":"Eur Heart J"},{"key":"hoi230003r36","article-title":"Serum neprilysin and its relationship to cardiovascular disease in the general population.","volume":"138","author":"Reddy","year":"2018","journal-title":"Circulation"},{"issue":"3","key":"hoi230003r37","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1161\/CIRCULATIONAHA.121.054892","article-title":"Effect of neprilysin inhibition on left ventricular remodeling in patients with asymptomatic left ventricular systolic dysfunction late after myocardial infarction.","volume":"144","author":"Docherty","year":"2021","journal-title":"Circulation"},{"issue":"4","key":"hoi230003r38","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1152\/japplphysiol.01261.2010","article-title":"Biological aortic age derived from the arterial pressure waveform.","volume":"110","author":"Shibata","year":"2011","journal-title":"J Appl Physiol (1985)"},{"issue":"1","key":"hoi230003r39","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1002\/ejhf.2015.17.issue-1","article-title":"Impact of chronic changes in arterial compliance and resistance on left ventricular ageing in humans.","volume":"17","author":"Wohlfahrt","year":"2015","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"hoi230003r40","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1152\/japplphysiol.00634.2017","article-title":"Exercise training improves blood flow to contracting skeletal muscle of older men via enhanced cGMP signaling.","volume":"124","author":"Piil","year":"2018","journal-title":"J Appl Physiol (1985)"},{"issue":"5","key":"hoi230003r41","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1161\/HYPERTENSIONAHA.109.146845","article-title":"Size, shape, and stamina: the impact of left ventricular geometry on exercise capacity.","volume":"55","author":"Lam","year":"2010","journal-title":"Hypertension"},{"issue":"12","key":"hoi230003r42","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1161\/CIRCULATIONAHA.121.054117","article-title":"One-year committed exercise training reverses abnormal left ventricular myocardial stiffness in patients with stage B heart failure with preserved ejection fraction.","volume":"144","author":"Hieda","year":"2021","journal-title":"Circulation"},{"issue":"7","key":"hoi230003r43","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.jcmg.2014.12.032","article-title":"Left atrium size in elite athletes.","volume":"8","author":"Iskandar","year":"2015","journal-title":"JACC Cardiovasc Imaging"},{"issue":"4","key":"hoi230003r44","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1161\/01.CIR.89.4.1580","article-title":"Endothelin in human congestive heart failure.","volume":"89","author":"Wei","year":"1994","journal-title":"Circulation"},{"issue":"5","key":"hoi230003r45","doi-asserted-by":"publisher","first-page":"E771","DOI":"10.1073\/pnas.1610968114","article-title":"Atrial natriuretic peptide regulates adipose tissue accumulation in adult atria.","volume":"114","author":"Suffee","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"hoi230003r46","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1002\/ejhf.v24.8","article-title":"Epicardial adipose tissue related to left atrial and ventricular function in heart failure with preserved versus reduced and mildly reduced ejection fraction.","volume":"24","author":"Jin","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"hoi230003r31","unstructured":"European Medicines Agency. Clinical safety data management: definitions and standards for expedited reporting. Accessed September 23, 2022. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/international-conference-harmonisation-technical-requirements-registration-pharmaceuticals-human-use_en-15.pdf"}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/articlepdf\/2802371\/jamacardiology_ledwidge_2023_oi_230003_1681233019.37012.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T15:08:41Z","timestamp":1681312121000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2802371"}},"subtitle":["The PARABLE Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2023,4,1]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2023.0065","relation":{},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4,1]]}}}